Clinical phenotypes and long-term outcomes of anti-SRP versus anti-HMGCR immune-mediated necrotising myopathy: a 13-year single-centre study
Our findings are in line with previous reporting, demonstrating that the majority of patients respond to immunosuppressive therapy, and the association of anti-SRP myopathy with more prominent systemic involvement. Anti-HMGCR antibody titres are a potentially valuable biomarker for disease activity and may have utility in guiding immunosuppression withdrawal.
Authors
- Anna S Herrey (ORCID: https://orcid.org/0000-0002-4681-6502)
- Thomas O Millner (ORCID: https://orcid.org/0000-0001-5638-3918)
- Silvia Marino (ORCID: https://orcid.org/0000-0002-9612-2883)
- Rhys Thomas
- Ann Dougan
- Aleksandar Radunović
- Kristina E N Clark (ORCID: https://orcid.org/0000-0002-5926-3900)
- Riyaz Patel (ORCID: https://orcid.org/0000-0003-4603-2393)
- Liz Walker
- Lisa M. Clayton (ORCID: https://orcid.org/0000-0002-1928-8054)
- Stephen Kelly
- Sadeer Fhadil
Institutions
- Barts Health NHS Trust (GB)
Publication Details
- Journal
- Clinical and Experimental Rheumatology
- Published
- 2025-03-21
- DOI
- https://doi.org/10.55563/clinexprheumatol/icqeff
- Primary Topic
- Inflammatory Myopathies and Dermatomyositis
- Type
- article
- Field-Weighted Citation Impact
- 0.00